Jim Rotolo
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2020First federal award
$6.6MFederal grants as PI10 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
10 awards · $6.6M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Apr 26, 2024 | NIH | SBIR Phase II Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $632K | Sapience Therapeutics Inc. |
| Jul 20, 2023 | NIH | SBIR Phase II Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $803K | Sapience Therapeutics Inc. |
| May 1, 2023 | NIH | SBIR Phase II Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $1.4M | Sapience Therapeutics Inc. |
| May 1, 2023 | NIH | SBIR Phase II Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $1.4M | Sapience Therapeutics Inc. |
| Aug 10, 2022 | NIH | SBIR Phase II Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $632K | Sapience Therapeutics Inc. |
| Apr 22, 2022 | NIH | SBIR Phase I Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $288K | Sapience Therapeutics Inc. |
| Sep 2, 2021 | NIH | SBIR Phase I Development of a cell-penetrating beta-catenin antagonist peptide as a therapeutic candidate for Wnt-driven breast cancer | $409K | Sapience Therapeutics Inc. |
| May 4, 2021 | NIH | SBIR Phase I Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $588K | Sapience Therapeutics Inc. |
| May 4, 2021 | NIH | SBIR Phase I Inhibition of SARS-CoV-2 infection with a pan-coronavirus anti-viral peptide | $300K | Sapience Therapeutics Inc. |
| Aug 5, 2020 | NIH | SBIR Phase I Efficacy and PK/PD of a C/EBP beta antagonist in orthotopic breast cancer | $255K | Sapience Therapeutics Inc. |
Peer ranks
Federal funding#156
Awards as PI#128
Patents#273
Companies
- Sapience Therapeutics Inc.Linked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.